Hepatitis C remains a serious public health problem. Exciting progress in understanding some of the basic biologic aspects of the hepatitis C virus (HCV) is ongoing, and potential alternative treatment regimens based on these findings are now being explored in clinical trials.
More than 2,500 physicians, researchers, and other scientists attended the 32nd Annual Meeting of the European Association for the Study of the Liver (EASL) in London, United Kingdom, April 9-12, 2011, to discuss the latest research and clinical practice regarding liver disease, including hepatitis C.
At a satellite symposium chaired by Professors (Barcelona, Spain) and Thierry Poynard (Paris, France) and attended by more than 1,400 meeting delegates, Doctor (Seattle, Washington, USA)
Discussed the current knowledge on HCV reproduction rates and rationale for daily interferon (IFN) alfa-2b induction therapy, and Doctor (Athens, Greece) presented preliminary findings from an ongoing clinical trial evaluating IFN alfa-2b induction dosing in patients with HCV infection.
Professor Poynard reviewed results of a meta-analysis of randomized, controlled trials indicating that IFN alfa-2b and ribavirin combination therapy significantly improves the sustained response rate in treatment-naive patients with HCV infection.Both comments and pings are currently closed.